US6821431029
© BusinessWire
24.12.2025
OMER
LISTED
NASDAQ
FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
News Preview
Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of...
Themefolio
Profiler
Peergroup
© BusinessWire
01.12.2025
OMER
LISTED
NASDAQ
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
News Preview
Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Zaltenibart is a first-in-class, late-stage clinical humanized monoclonal antibody targeting MASP-3 – the most upstream and key activator of the alternative...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2025
OMER
LISTED
NASDAQ
Omeros Corporation Reports Third Quarter 2025 Financial Results
News Preview
Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2025, which include:
Net loss for the third quarter of 2025 was $30.9 million, or $0.47 per share, compared to a net loss of $32.2 million, or $0.56 per share for the third quarter of 2024....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
11.11.2025
OMER
LISTED
NASDAQ
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
News Preview
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial r...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
16.10.2025
OMER
LISTED
NASDAQ
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
News Preview
Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing survival outcomes in adult patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab across both the pivotal clinical t...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
OMER
LISTED
NASDAQ
Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
News Preview
Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and pediatric patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab through a global expanded access program (EAP). Na...
Themefolio
Profiler
Peergroup
© BusinessWire
14.08.2025
OMER
LISTED
NASDAQ
Omeros Corporation Reports Second Quarter 2025 Financial Results
News Preview
Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include:
Net loss for the second quarter of 2025 was $25.4 million, or $0.43 per share, compared to a net loss of $56.0 million, or $0.97 per share for the second quarter of 2024. Fo...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
31.07.2025
OMER
LISTED
NASDAQ
D. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Direct Offering
News Preview
NEW YORK CITY, NEW YORK / ACCESS Newswire / July 31, 2025 / On July 24, 2025, Omeros Corporation (Nasdaq:OMER) ("Omeros" or the "Company") entered into a securities purchase agreement with Polar Asset Management Partners to sell approximately $22,000,000 of its common stock in a registered direct offering (the "Transaction&...
Themefolio
Profiler
Peergroup
© BusinessWire
25.07.2025
OMER
LISTED
NASDAQ
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering
News Preview
Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) announced that on July 24, 2025 it entered into a securities purchase agreement with Polar Asset Management Partners to sell approximately $22 million of its common stock in a registered direct offering.
Under the terms of the securities purchase agreement, the Company has agreed to s...
Themefolio
Profiler
Peergroup
© BusinessWire
27.06.2025
OMER
LISTED
NASDAQ
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
News Preview
Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
The MAA includes response-based analyses in narsoplimab-treated TA-TM...
Themefolio
Profiler
Peergroup
© BusinessWire
24.06.2025
OMER
LISTED
NASDAQ
Omeros Announces Webcast Details for Annual Meeting of Shareholders
News Preview
Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 27, 2025, starting at 10:00 a.m. Pacific Time.
The live webcast can be accessed through the virtual shareholder meeting website at www.virtualshareholdermeeting.com/OMER20...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
OMER
LISTED
NASDAQ
Omeros Corporation Reports First Quarter 2025 Financial Results
News Preview
Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2025, which include:
Net loss for the first quarter of 2025 was $33.5 million, or $0.58 per share, compared to a net loss of $37.2 million, or $0.63 per share for the first quarter of 2024.
At...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
12.05.2025
OMER
LISTED
NASDAQ
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
News Preview
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended March 31, 2025, on Thursday, May 15, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as...
Themefolio
Profiler
Peergroup
© BusinessWire
12.05.2025
OMER
LISTED
NASDAQ
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
News Preview
Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) today announced that it has entered into exchange agreements (the “Exchange Agreements”) with a limited number of investors who are holders of the Company’s 5.25% Convertible Senior Notes due 2026 (the “2026 Convertible Notes”) to exchange, on a one-for-one basis, $70.5 million aggregat...
Themefolio
Profiler
Peergroup
© BusinessWire
06.05.2025
OMER
LISTED
NASDAQ
FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date
News Preview
Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The resubmission was classified as a Class 2 r...
Themefolio
Profiler
Peergroup
© BusinessWire
10.04.2025
OMER
LISTED
NASDAQ
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
News Preview
Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia (AML). AML is the most fatal form of leukemia and accounts for approximately 80 percent of acute leukemias in adults and one-third of all cancers affec...
Themefolio
Profiler
Peergroup
© BusinessWire
08.04.2025
OMER
LISTED
NASDAQ
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
News Preview
Omeros Corporation (Nasdaq: OMER) today announced that the first public presentation of its proprietary Targeted Complement Activating TherapyTM (T-CATTM) platform will occur at the European Congress on Infectious Diseases 2025 in Rome, Italy on Monday, April 14. The plenum presentation, titled Augmenting cytotoxicity of pathogen-specific antibodi...
Themefolio
Profiler
Peergroup
© BusinessWire
31.03.2025
OMER
LISTED
NASDAQ
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
News Preview
Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2024, which include:
Net loss for the fourth quarter of 2024 was $31.4 million, or $0.54 per share, compared to a net loss of $32.2 million, or $0.56 per share for the third quarter...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
OMER
LISTED
NASDAQ
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
News Preview
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2024, on Monday, March 31, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financia...
Themefolio
Profiler
Peergroup
© BusinessWire
21.03.2025
OMER
LISTED
NASDAQ
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
News Preview
Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH). Zaltenibart (OMS906) is Omeros’ investigational inhibitor of MASP-3, the key and most proximal activator of the alternative pathway of...
Themefolio
Profiler
Peergroup
© BusinessWire
13.03.2025
OMER
LISTED
NASDAQ
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
News Preview
Omeros Corporation (Nasdaq: OMER) today announced that it has received a funding commitment from the National Institute on Drug Abuse (NIDA) for the upcoming year (April 1, 2025 through March 31, 2026) in the amount of $4.02 million for clinical development of its lead orally administered phosphodiesterase 7 (PDE7) inhibitor OMS527 to treat cocain...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
OMER
LISTED
NASDAQ
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
News Preview
Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros’ first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatenin...
Themefolio
Profiler
Peergroup
© BusinessWire
14.02.2025
OMER
LISTED
NASDAQ
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
News Preview
Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research....
Themefolio
Profiler
Peergroup
© BusinessWire
10.02.2025
OMER
LISTED
NASDAQ
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
News Preview
Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for International Blood and Marrow Transplant Research, to be held February 12-15, 2025 in Honolu...
Themefolio
Profiler
Peergroup
© BusinessWire
16.01.2025
OMER
LISTED
NASDAQ
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
News Preview
Omeros Corporation (Nasdaq: OMER) today announced statistical sensitivity analysis results related to the primary endpoint analysis for narsoplimab, Omeros’ first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-th...
Themefolio
Profiler
Peergroup
© BusinessWire
19.12.2024
OMER
LISTED
NASDAQ
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
News Preview
Omeros Corporation (Nasdaq: OMER) today announced that an independent statistical group has completed the primary statistical analysis agreed with the FDA for narsoplimab, Omeros’ first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopa...
Themefolio
Profiler
Peergroup
© BusinessWire
10.12.2024
OMER
LISTED
NASDAQ
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
News Preview
Omeros Corporation (Nasdaq: OMER) today announced that two posters directed to zaltenibart (OMS906), Omeros’ investigational inhibitor of MASP-3, the key and most proximal activator of the alternative pathway of complement, were presented at the 66th Annual Meeting of the American Society of Hematology (ASH) yesterday in San Diego. The posters, bo...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2024
OMER
LISTED
NASDAQ
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
News Preview
Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros’ investigational inhibitor of MASP-3, the key activator of the alternative pathway of complement, will be presented at the 66th Annual Meeting of the American Society of Hematology (ASH), to be held December 7-10, 2024 in San Diego. The za...
Themefolio
Profiler
Peergroup
© BusinessWire
21.11.2024
OMER
LISTED
NASDAQ
Omeros Corporation Provides Update on Progress Toward BLA Resubmission
News Preview
Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application (“BLA”) for narsoplimab, the company’s first-in-class antibody targeting MASP-2, the effector enzyme of the lectin pathway of complement, in hematopoietic stem cell transplant-associated thrombotic microangio...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
OMER
LISTED
NASDAQ
Omeros Corporation Reports Third Quarter 2024 Financial Results
News Preview
Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2024, which include:
Net loss for the third quarter of 2024 was $32.2 million, or $0.56 per share, compared to a net loss of $37.8 million, or $0.60 per share for the third quarter of 2023....
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2024
OMER
LISTED
NASDAQ
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
News Preview
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
OMER
LISTED
NASDAQ
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
News Preview
Omeros Corporation today announced that zaltenibart (OMS906) has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for the treatment of complement 3 glomerulopathy (C3G), an ultra-rare, progressive renal disorder primarily afflicting children and young adults. Caused by dysregulation of the alternative pa...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
